Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma episode artwork

EPISODE · Feb 12, 2024 · 20 MIN

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

from Medical Digest & Congress Report · host Medical Congress News

We asked Professor David F. McDermott, investigator of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024. Video: https://medicaldigest.org/scientific-contents/standalonecontent:overall-survival-results-keynote-564-adjuvant-pembrolizumab-versus-placebo-renal-cell-carcinoma

Episode metadata supplied by the publisher feed · Published Feb 12, 2024

Embed this episode

Ready to play

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

0:00 20:13

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 20 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on February 12, 2024.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!